血清HBeAg定量检测技术新进展  

Advances in the quantitative of serum HBeAg and its clinical significance

作　　者：陈秀丽[1] 张学东 戴二黑[1] CHEN Xiuli;ZHANG Xuedong;DAI Erhei(Division of Liver Disease,The Fifth Hospital of Shijiazhuang,Hebei Medical University,Hebei,Shijiazhuang,China 050021;Autobio Diagnostics Co.,Ltd,National Eco&Tech development zone,Henan,Zhengzhou,China 450016)

机构地区：[1]河北医科大学附属石家庄市第五医院,肝病研究所,河北石家庄050021 [2]郑州安图生物工程股份有限公司,研发中心,河南郑州450016

出　　处：《分子诊断与治疗杂志》2020年第3期391-395,共5页Journal of Molecular Diagnostics and Therapy

基　　金：河北省2018年度医学科学研究重点课题计划资助项目(20181079)。

摘　　要：近年来,乙型肝炎e抗原(hepatitis B e Antigen,HBeAg)定量检测技术不断创新发展,由定性、半定量,发展至目前真正意义上的定量检测,并在临床上逐步推广应用。血清HBeAg定量水平与病毒复制、肝组织损伤以及谷氨酸-丙酮酸转氨酶(ALT)升高等指标密切相关。基线HBeAg定量水平可预测聚乙二醇化干扰素(PEG-IFN)、核苷(酸)类似物(NAs)的疗效;治疗过程中实时监测HBeAg降低水平及幅度,可更加精准预测抗病毒药物的疗效,有助于指导临床医师针对不同患者制定个体化治疗方案。本文就目前HBeAg定量检测技术及其在临床应用方面的最新进展做一综述,旨在为临床医师判断患者病情变化,制定优化治疗方案等方面提供理论依据。In recent years,the quantitative technology of serum Hepatitis B e Antigen has been developed continuously,from qualitative,semi-quantitative,to the real sense of quantitative detection. It is gradually popularized and applied in clinical practice. Serum HBeAg level is well correlated with virus replication,liver tissue damage and elevated Alanine aminotransferase. Baseline HBeAg quantification can predict the efficacy of Peginterferon and nucleoside analogues. Real-time monitoring of HBeAg level can predict the efficacy more accurately during the treatment,and guide clinicians to make individualized plan.This review summarizes the current progress in the field of HBeAg quantitative detection technology and its clinical application.The purpose is to provide a theoretical basis for clinicians to judge the illness and guide the selection of treatment programs.

关 键 词：乙型肝炎E抗原 定量检测 相关研究 

分 类 号：R512.62[医药卫生—内科学] R446.6[医药卫生—临床医学]